6. Lenvatinib: Precision Attack on Cancer Cells
Another potent tyrosine kinase inhibitor making a significant impact in thyroid cancer treatment is Lenvatinib. Much like Sorafenib, Lenvatinib works by precisely targeting proteins involved in the growth, division, and blood supply of cancer cells. It has a particular role in treating differentiated thyroid cancer that has become refractory to radioactive iodine therapy.
Lenvatinib’s mechanism of action includes obstructing the formation of new blood vessels (angiogenesis) necessary for tumors to grow and proliferate. By cutting off this supply line, it helps restrict the growth and spread of cancer cells.
While Lenvatinib’s side effects can include hypertension, fatigue, and diarrhea, these are typically manageable with dose adjustments and supportive care. The benefits, in terms of progression-free survival for patients with advanced thyroid cancer, often outweigh these side effects. The incorporation of targeted therapies like Lenvatinib into treatment regimens represents a significant leap forward in thyroid cancer care, providing new avenues for those with advanced disease. (6)
